PMID- 30562171
OWN - NLM
STAT- MEDLINE
DCOM- 20200128
LR  - 20200309
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 33
IP  - 2
DP  - 2019 Feb 1
TI  - HIV latency can be established in proliferating and nonproliferating resting CD4+ 
      T cells in vitro: implications for latency reversal.
PG  - 199-209
LID - 10.1097/QAD.0000000000002075 [doi]
AB  - OBJECTIVE: To determine whether latency can be established and reversed in both 
      proliferating and nonproliferating CD4+ T cells in the same model in vitro. 
      METHODS: Activated CD4+ T cells were infected with either a nonreplication 
      competent, luciferase reporter virus or wild-type full-length enhanced green 
      fluorescent protein (EGFP) reporter virus and cultured for 12 days. The cells 
      were then sorted by flow cytometry to obtain two distinct T-cell populations that 
      did not express the T-cell activation markers, CD69, CD25 and human leukocyte 
      antigen (HLA)-DR: CD69CD25HLA-DR small cells (nonblasts) that had not 
      proliferated in vitro following mitogen stimulation and CD69CD25HLA-DR large 
      cells (which we here call transitional blasts) that had proliferated. The cells 
      were then reactivated with latency-reversing agents and either luciferase or EGFP 
      quantified. RESULTS: Inducible luciferase expression, consistent with latent 
      infection, was observed in nonblasts and transitional blasts following 
      stimulation with either phorbol-myristate-acetate/phytohemagglutinin (3.8 +/- 1 and 
      2.9 +/- 0.5 fold above dimethyl sulfoxide, respectively) or romidepsin (2.1 +/- 0.6 
      and 1.8 +/- 0.2 fold above dimethyl sulfoxide, respectively). Constitutive 
      expression of luciferase was higher in transitional blasts compared with 
      nonblasts. Using wild-type full-length EGFP reporter virus, inducible virus was 
      observed in nonblasts but not in transitional blasts. No significant difference 
      was observed in the response to latency-reversing agents in either nonblasts or 
      transitional blasts. CONCLUSION: HIV latency can be established in vitro in 
      resting T cells that have not proliferated (nonblasts) and blasts that have 
      proliferated (transitional blasts). This model could potentially be used to 
      assess new strategies to eliminate latency.
FAU - Moso, Michael A
AU  - Moso MA
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
AD  - Department of Infectious Diseases, Alfred Hospital and Monash University.
AD  - Centre for Biomedical Research, Burnet Institute.
FAU - Anderson, Jenny L
AU  - Anderson JL
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
FAU - Adikari, Samantha
AU  - Adikari S
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
FAU - Gray, Lachlan R
AU  - Gray LR
AD  - Department of Infectious Diseases, Alfred Hospital and Monash University.
AD  - Centre for Biomedical Research, Burnet Institute.
FAU - Khoury, Georges
AU  - Khoury G
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
AD  - Department of Microbiology and Immunology at The Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne, Melbourne, Victoria.
FAU - Chang, Judy J
AU  - Chang JJ
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
FAU - Jacobson, Jonathan C
AU  - Jacobson JC
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
AD  - Department of Microbiology and Immunology at The Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne, Melbourne, Victoria.
FAU - Ellett, Anne M
AU  - Ellett AM
AD  - Centre for Biomedical Research, Burnet Institute.
FAU - Cheng, Wan-Jung
AU  - Cheng WJ
AD  - Centre for Biomedical Research, Burnet Institute.
FAU - Saleh, Suha
AU  - Saleh S
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
FAU - Zaunders, John J
AU  - Zaunders JJ
AD  - Kirby Institute, University of New South Wales.
AD  - Centre for Applied Medical Research, St. Vincent's Hospital, Sydney, New South 
      Wales.
FAU - Purcell, Damian F J
AU  - Purcell DFJ
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
AD  - Department of Microbiology and Immunology at The Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne, Melbourne, Victoria.
FAU - Cameron, Paul U
AU  - Cameron PU
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
AD  - Department of Infectious Diseases, Alfred Hospital and Monash University.
AD  - Centre for Biomedical Research, Burnet Institute.
FAU - Churchill, Melissa J
AU  - Churchill MJ
AD  - School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, 
      Australia.
FAU - Lewin, Sharon R
AU  - Lewin SR
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
AD  - Department of Infectious Diseases, Alfred Hospital and Monash University.
FAU - Lu, Hao K
AU  - Lu HK
AD  - The Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital.
LA  - eng
GR  - U19 AI096109/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (CD69 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (IL2RA protein, human)
RN  - 0 (Interleukin-2 Receptor alpha Subunit)
RN  - 0 (Lectins, C-Type)
SB  - IM
MH  - Antigens, CD/analysis
MH  - Antigens, Differentiation, T-Lymphocyte/analysis
MH  - CD4-Positive T-Lymphocytes/chemistry/classification/*physiology/*virology
MH  - *Cell Proliferation
MH  - Cells, Cultured
MH  - Flow Cytometry
MH  - HIV/*physiology
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - Interleukin-2 Receptor alpha Subunit/analysis
MH  - Lectins, C-Type/analysis
MH  - Staining and Labeling
MH  - *Virus Latency
PMC - PMC6319264
MID - NIHMS1512594
COIS- Conflicts of Interest The authors declare that they have no competing interests.
EDAT- 2018/12/19 06:00
MHDA- 2020/01/29 06:00
PMCR- 2020/02/01
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2020/01/29 06:00 [medline]
PHST- 2020/02/01 00:00 [pmc-release]
AID - 00002030-201902010-00003 [pii]
AID - 10.1097/QAD.0000000000002075 [doi]
PST - ppublish
SO  - AIDS. 2019 Feb 1;33(2):199-209. doi: 10.1097/QAD.0000000000002075.